---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-076039"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:06:33.719554+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed

## Summary
- Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).
- Net loss $1.5M ($0.03 EPS) vs $2.8M ($0.10 EPS); operating expenses down 9% to $2.8M.
- Oversubscribed $8.2M capital raise closed April 2025; cash $8.0M, no debt.
- FY2025 product revenue guidance $8-10M (132-190% growth); gross margin guidance raised to 50-53%.
- Milestones: FDA 510(k) filed for trigeminal ablation; first patient seizure-free 1-year; sEEG drug delivery order.

## SEC filing metadata
- accession: 0001213900-25-076039
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025076039/0001213900-25-076039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025076039/ea0252735-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-076039
- JSON: https://secwatch.observer/filing/0001213900-25-076039.json
- Plain text: https://secwatch.observer/filing/0001213900-25-076039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.